Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients
Background: Platelets (PLT) have a significant effect in promoting cancer progression and hematogenous metastasis. However, the effect of platelet activation-related lncRNAs (PLT-related lncRNAs) in gastric cancer (GC) is still poorly understood. In this study, we screened and validated PLT-related...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.965033/full |
| _version_ | 1798033290442047488 |
|---|---|
| author | Mingjie Yuan Mingjie Yuan Yanfei Jia Yuanxin Xing Yunshan Wang Yunyun Liu Yunyun Liu Xiangdong Liu Duanrui Liu |
| author_facet | Mingjie Yuan Mingjie Yuan Yanfei Jia Yuanxin Xing Yunshan Wang Yunyun Liu Yunyun Liu Xiangdong Liu Duanrui Liu |
| author_sort | Mingjie Yuan |
| collection | DOAJ |
| description | Background: Platelets (PLT) have a significant effect in promoting cancer progression and hematogenous metastasis. However, the effect of platelet activation-related lncRNAs (PLT-related lncRNAs) in gastric cancer (GC) is still poorly understood. In this study, we screened and validated PLT-related lncRNAs as potential biomarkers for prognosis and immunotherapy in GC patients.Methods: We obtained relevant datasets from the Cancer Genome Atlas (TCGA) and Gene Ontology (GO) Resource Database. Pearson correlation analysis was used to identify PLT-related lncRNAs. By using the univariate, least absolute shrinkage and selection operator (LASSO) Cox regression analyses, we constructed the PLT-related lncRNAs model. Kaplan-Meier survival analysis, univariate, multivariate Cox regression analysis, and nomogram were used to verify the model. The Gene Set Enrichment Analysis (GSEA), drug screening, tumor immune microenvironment analysis, epithelial-mesenchymal transition (EMT), and DNA methylation regulators correlation analysis were performed in the high- and low-risk groups. Patients were regrouped based on the risk model, and candidate compounds and immunotherapeutic responses aimed at GC subgroups were also identified. The expression of seven PLT-related lncRNAs was validated in clinical medical samples using quantitative reverse transcription-polymerase chain reaction (qRT-PCR).Results: In this study, a risk prediction model was established using seven PLT-related lncRNAs -(AL355574.1, LINC01697, AC002401.4, AC129507.1, AL513123.1, LINC01094, and AL356417.2), whose expression were validated in GC patients. Kaplan-Meier survival analysis, the receiver operating characteristic (ROC) curve analysis, univariate, multivariate Cox regression analysis verified the accuracy of the model. We screened multiple targeted drugs for the high-risk patients. Patients in the high-risk group had a poorer prognosis since low infiltration of immune killer cells, activation of immunosuppressive pathways, and poor response to immunotherapy. In addition, we revealed a close relationship between risk scores and EMT and DNA methylation regulators. The nomogram based on risk score suggested a good ability to predict prognosis and high clinical benefits.Conclusion: Our findings provide new insights into how PLT-related lncRNAs biomarkers affect prognosis and immunotherapy. Also, these lncRNAs may become potential biomarkers and therapeutic targets for GC patients. |
| first_indexed | 2024-04-11T20:27:56Z |
| format | Article |
| id | doaj.art-31e2159f420842debadd2c7f829e925a |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-11T20:27:56Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-31e2159f420842debadd2c7f829e925a2022-12-22T04:04:36ZengFrontiers Media S.A.Frontiers in Genetics1664-80212022-09-011310.3389/fgene.2022.965033965033Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patientsMingjie Yuan0Mingjie Yuan1Yanfei Jia2Yuanxin Xing3Yunshan Wang4Yunyun Liu5Yunyun Liu6Xiangdong Liu7Duanrui Liu8Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, ChinaDepartment of Laboratory, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, ChinaResearch Center of Basic Medicine, Jinan Central Hospital, Shandong First Medical University, Jinan, ChinaResearch Center of Basic Medicine, Jinan Central Hospital, Shandong First Medical University, Jinan, ChinaResearch Center of Basic Medicine, Jinan Central Hospital, Shandong First Medical University, Jinan, ChinaResearch Center of Basic Medicine, Jinan Central Hospital, Shandong First Medical University, Jinan, ChinaResearch Center of Basic Medicine, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, ChinaDepartment of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, ChinaDepartment of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, ChinaBackground: Platelets (PLT) have a significant effect in promoting cancer progression and hematogenous metastasis. However, the effect of platelet activation-related lncRNAs (PLT-related lncRNAs) in gastric cancer (GC) is still poorly understood. In this study, we screened and validated PLT-related lncRNAs as potential biomarkers for prognosis and immunotherapy in GC patients.Methods: We obtained relevant datasets from the Cancer Genome Atlas (TCGA) and Gene Ontology (GO) Resource Database. Pearson correlation analysis was used to identify PLT-related lncRNAs. By using the univariate, least absolute shrinkage and selection operator (LASSO) Cox regression analyses, we constructed the PLT-related lncRNAs model. Kaplan-Meier survival analysis, univariate, multivariate Cox regression analysis, and nomogram were used to verify the model. The Gene Set Enrichment Analysis (GSEA), drug screening, tumor immune microenvironment analysis, epithelial-mesenchymal transition (EMT), and DNA methylation regulators correlation analysis were performed in the high- and low-risk groups. Patients were regrouped based on the risk model, and candidate compounds and immunotherapeutic responses aimed at GC subgroups were also identified. The expression of seven PLT-related lncRNAs was validated in clinical medical samples using quantitative reverse transcription-polymerase chain reaction (qRT-PCR).Results: In this study, a risk prediction model was established using seven PLT-related lncRNAs -(AL355574.1, LINC01697, AC002401.4, AC129507.1, AL513123.1, LINC01094, and AL356417.2), whose expression were validated in GC patients. Kaplan-Meier survival analysis, the receiver operating characteristic (ROC) curve analysis, univariate, multivariate Cox regression analysis verified the accuracy of the model. We screened multiple targeted drugs for the high-risk patients. Patients in the high-risk group had a poorer prognosis since low infiltration of immune killer cells, activation of immunosuppressive pathways, and poor response to immunotherapy. In addition, we revealed a close relationship between risk scores and EMT and DNA methylation regulators. The nomogram based on risk score suggested a good ability to predict prognosis and high clinical benefits.Conclusion: Our findings provide new insights into how PLT-related lncRNAs biomarkers affect prognosis and immunotherapy. Also, these lncRNAs may become potential biomarkers and therapeutic targets for GC patients.https://www.frontiersin.org/articles/10.3389/fgene.2022.965033/fullgastric cancerimmunotherapyplateletlncRNAprognosis |
| spellingShingle | Mingjie Yuan Mingjie Yuan Yanfei Jia Yuanxin Xing Yunshan Wang Yunyun Liu Yunyun Liu Xiangdong Liu Duanrui Liu Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients Frontiers in Genetics gastric cancer immunotherapy platelet lncRNA prognosis |
| title | Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients |
| title_full | Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients |
| title_fullStr | Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients |
| title_full_unstemmed | Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients |
| title_short | Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients |
| title_sort | screening and validation of platelet activation related lncrnas as potential biomarkers for prognosis and immunotherapy in gastric cancer patients |
| topic | gastric cancer immunotherapy platelet lncRNA prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2022.965033/full |
| work_keys_str_mv | AT mingjieyuan screeningandvalidationofplateletactivationrelatedlncrnasaspotentialbiomarkersforprognosisandimmunotherapyingastriccancerpatients AT mingjieyuan screeningandvalidationofplateletactivationrelatedlncrnasaspotentialbiomarkersforprognosisandimmunotherapyingastriccancerpatients AT yanfeijia screeningandvalidationofplateletactivationrelatedlncrnasaspotentialbiomarkersforprognosisandimmunotherapyingastriccancerpatients AT yuanxinxing screeningandvalidationofplateletactivationrelatedlncrnasaspotentialbiomarkersforprognosisandimmunotherapyingastriccancerpatients AT yunshanwang screeningandvalidationofplateletactivationrelatedlncrnasaspotentialbiomarkersforprognosisandimmunotherapyingastriccancerpatients AT yunyunliu screeningandvalidationofplateletactivationrelatedlncrnasaspotentialbiomarkersforprognosisandimmunotherapyingastriccancerpatients AT yunyunliu screeningandvalidationofplateletactivationrelatedlncrnasaspotentialbiomarkersforprognosisandimmunotherapyingastriccancerpatients AT xiangdongliu screeningandvalidationofplateletactivationrelatedlncrnasaspotentialbiomarkersforprognosisandimmunotherapyingastriccancerpatients AT duanruiliu screeningandvalidationofplateletactivationrelatedlncrnasaspotentialbiomarkersforprognosisandimmunotherapyingastriccancerpatients |